Comprehending the genetic background of pediatric Acute Myeloid Leukemia (AML) is the key to risk stratification. Next Generation Sequencing (NGS) technology uses target panels that may detect additional genetic subsets. The study describes the experience of using NGS at an institution. Patients who showed poor outcome aberration were referred to hematopoietic stem cell transplant (HSCT). 11 patients were tested. Aberrations were found in all subjects, indicating referral to HSCT in first remission in 2 cases and helping to outline the genetic features in all cases. NGS is a valuable tool in the precision medicine era and should be widely accessible.

A document by Fernanda Mota. Click on the document to view its contents.

Severe SARS-CoV-2 infections in pediatrics are rare and usually presented as multisystem inflammatory syndrome in children. There are few descriptions about pediatric oncology patients. We describe a case of 5-year-old male with acute myeloid leukemia. He presented febrile neutropenia with skin lesions and progressive clinical worsening. He had positive RT-PCR test for SARS-CoV-2 and criteria for MIS-C. He received methylprednisolone, immunoglobulin and granulocyte-colony-stimulating factor. Anti-interleukin 6 was administrated due to severe lung disease and refractory to treatment, presenting response and slow clinical recovery. Chemotherapy was restarted, he didn't present relapse during treatment and has no sequelae of COVID-19.